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Abstract
Background:  As a proportion of high grade cervical intraepithelial neoplasia (CIN2/3) are
associated with equivocal cervical smears, which show borderline or mild dyskaryosis, follow up
with repeat smears, colposcopy and biopsy is required. Since infection with oncogenic Human
Papilloma Virus (HR HPV) has been found to be associated with the development of cervical cancer,
HRHPV testing appears to be an alternative.
Objective: The present study assesses if HRHPV testing can predict CIN2/3 in women referred
for mild dyskaryosis and borderline cytological changes in an health authority with a referral policy
to colposcopy after one single mild dyskaryotic Pap smear.
Study design: The HPV DNA Hybrid Capture II (Digene/Abbott, Maidenhead) was evaluated on
110 consenting women with mild dyskaryosis and 23 women with persistent borderline changes,
who were referred for colposcopy between May and November 2001. A cost comparison between
two referral policies was performed.
Results: CIN2/3 was diagnosed histologically in 30 of 133 women (22%) with minor cytological
abnormalities. As the Receiver Operator Characteristics plot suggested a cut-off of 3 pg/ml the
HRHPV HCII was evaluated at 3 RLU (relative light units) and at the manufacturer's
recommendation of 1 RLU. At both cut-offs sensitivity and negative predictive value were high at
97%. Specificity was low at 37% at a cut-off of 1 pg/ml and 46% at a cut-off of 3 RLU. To remain
cost neutral in comparison to immediate colposcopy the costs for one HR HPV HC II must not
exceed £34.37 per test at a cut off of 3 pg/ml.
Conclusion: The negative likelihood ratio (NLR) was of good diagnostic value with 0.089 at 1 RLU
and 0.072 at 3 RLU, which reduces the post-test probability for CIN2/3 to 2% in this population.
Women with minor cytological disorders can be excluded from colposcopy on a negative HR HPV
result.
Specificity can be improved by restricting HR HPV testing to women with persistent borderline 
cytological changes or to women over 30 years.
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Background
Oncogenic Human Papilloma Virus (HR HPV) genome
could be found in 99.7% of 942 histologically proven cer-
vix carcinoma [1]. HPV gene product E6 is thought to
degrade the tumour suppressor protein p53 destabilizing
the cell cycle, which leads to cervical cancer in susceptible
individuals [2]. Cytological screening has reduced the
annual incidence of cervical carcinoma from 17/100000
to 8.5/100000 in the last 20 years in the UK [3]. However
up to 30% of high grade cervical intraepithelial neoplasia
(CIN2/3) are associated with equivocal cervical smears,
which show borderline or mild dyskaryosis [3]. This
requires follow up of women with minor cytological
abnormalities with repeat smears, colposcopy and biopsy.
Adjunctive HRHPV testing could triage women for colpos-
copy. Liquid based cytology, which is presently assessed
in some UK laboratories, allows adjunctive HPV testing
using a commercial gene probe HPV DNA Hybrid Capture
II (Digene/Abbott, Maidenhead) without the need for an
additional specimen. NHS Cancer Screening Programme
(NHSCSP) guidelines stipulate referral after two mild dys-
karyotic smears or three borderline smear, whereas the
health authority in North West London recommends
referral after one mild dyskaryosis in order to improve
coverage and follow-up in a population with a high
mobility [4]. Despite of this different referral policy the
CIN2/3 prevalence is similar to other colposcopy clinics
with 20% [3].
We evaluated the performance of the Hybrid Capture HPV
DNA test on liquid based cytology for the diagnosis of
CIN2/3 in women referred to colposcopy clinic of West
Middlesex University Hospital (WMUH) after three bor-
derline or one mild dyskaryosis smear. A cost comparison
between the conventional referral strategy and triage for
colposcopy by positive HPV test was performed.
Materials and methods
Patients
Between May and November 2001 146 women were
referred to the colposcopy clinic of West Middlesex Uni-
versity Hospital for minor cytological abnormalities in
their cervical smear. The time period between abnormal
Pap smear and colposcopy did not exceed three months
(median = 4 weeks). All women gave their consent. We
had received ethical approval from the Hounslow District
Research Ethics committee to perform the study. The
smear was collected by rotating a cervical broom
(Papette® Wallach Surgical, Orange CT) ten times around
the cervical os and rinsing it into ten ml of PreservCyt®
(Cytyc corporation, Boxborough, MA), from which a Thin
prep Pap slide was prepared and the HPV test performed.
Colposcopy was performed on all women and a punch
biopsy was taken from suspicious areas of the cervix. If
colposcopic findings were normal, no biopsy was taken
and the case was classified as absence of CIN.
Cytology and histology
Cytopathologists at Quest Diagnostics classified Pap
smears into borderline, mild, moderate and severe dys-
karyosis. Punch biopsies were classified by two consultant
histopathologists at West Middlesex University Hospital
as CIN2/3 and CIN1 and HPV typical changes. The his-
topathologists were blinded to HPV results as were the
microbiologists to the histology results at the time of HPV
testing.
Hybrid capture HPV DNA test
The Hybrid capture II HPV DNA test (Digene/Abbott,
Maidenhead) was performed on liquid based cytology
specimens. The RNA probe mix for the detection of high
risk HPV types 16,18,31,33,35,39,45,51,52,56, 58,59 and
68 was used according to the manufacturer's instructions.
Signal amplification is based on immunocapture of DNA/
RNA hybrids and subsequent EIA with a chemilumines-
cent reporter system. The results are given as relative light
unit (RLU) ratio. As the RLU ratio is the ratio of light emit-
ted by the specimen to the light emitted from the mean
RLU of triplicate positive control specimens containing 1
pg/ml of HPV DNA (5000 copies of HPV genome)it is a
semiquantitativ estimate of viral load in the specimen.
Cost comparison
The cost of the conventional strategy to perform colpos-
copy on all women with minor cytological disorders were
compared with triaging women to colposcopy only if they
had a positive HRHPV in addition to their minor cytolog-
ical abnormality.
Costings are specified on NHS health care resource group
(HRG) level, which defined the costs for gynaecological
outpatient procedures, according to which colposcopy
including biopsy amounts to £93.28 per procedure [5].
The cost neutral price for one HRHPV HCII test was calcu-
lated by assessing the savings which are achieved by not
performing colposcopy in women who test HRHPV
negative.
As liquid based cytology has been introduced into the col-
poscopy clinic few years ago, no additional costs for cervi-
cal swabs accrued. Six monthly follow up Pap smears are
required after a negative HRHPV test as well as after col-
poscopy, which makes cytological follow up cost neutral
on comparison.
Statistical methods
For statistical analysis the Excel (Microsoft Windows 97)
compatible Analyse-it program (ANALYSE-IT SOFTWARE
LTD) was used.BMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/23
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Continuous variables were compared by one-way analysis
of variance and Mann-Whitney U-test. Difference between
proportions was analysed by Normal test. Association
between categorical variables was assessed by Chi-square
test. Test indices were given with the 95% confidence
intervals.
For sample size calculations we assumed that 40% of
women without CIN2/3 were infected by HRHPV. Thus to
detect a minimum odds ratio of 17 and to give the study
a power of 80% 11 CIN2/3 cases and four times as many
controls (n = 40) would be required at a confidence level
of 95%. If 70% of women without CIN2/3 were infected
23 cases and 92 controls are necessary.
The Bayes theorem was applied to arrive at the post test
probability.
Results
Over five months 146 women gave their consent for an
HPV test, of these six were excluded for previous LLETZ,
two for an inadequate biopsy specimen and five for a low
cell count in the liquid based cytology, which does not
allow an additional HPV test. The mean age of the remain-
ing 133 women was 31 years (SD = 10y and median = 30
years). One hundred and eight women underwent colpo-
scopically directed punch biopsy and in 25 women the
cervix did not show any abnormalities, which would
require biopsy.
Although the median of the high-risk HPV load rose with
increasing CIN grade, the difference of means between
different grades of CIN or between presence and absence
of CIN was not significant in parametric tests (p > 0.05,
one way analysis of variance), but the medians differed
significantly (p < 0.02, Mann-Whitney U-test) (table 1).
To determine a cut-off for a positive result a receiver-oper-
ator characteristics (ROC) plot was constructed (see figure
1). At 1 RLU, which is the cut-off recommended by the
manufacturer, the sensitivity amounted to 97% but the
false positive rate yielded 63%. At 3 RLU the sensitivity
was still 97% and specificity improved to 46%. At higher
concentrations sensitivity dropped below 90%. As HPV
testing is a screening test the sensitivity should be high in
order not to miss any precancerous lesions. False positive
results will be corrected by biopsy results. Thus the assay
performance was evaluated at the manufacturer's recom-
mended threshold of 1 RLU and at the apparent optimal
cut-off of 3 RLU.
At a cut-off of 1RLU the sensitivity of the HCII for high-
risk HPV in this population amounted to 97% (CI 91%-
103%) and the negative predictive value was 97% (CI
92%-102%). Specificity and positive predictive value
ranged low with 37% (CI 28%-46%) and 30% (CI 21%-
39%) (see table 2). The odds ratio of a positive HCII test
for CIN2 and worse was 17.1 (CI 2.46–686). Detection of
high-risk HPV types was strongly associated with CIN2 or
worse (p < 0.001, Chi-square test).
The pre-test prevalence of CIN2/3 in this population was
22.6% (CI 15%-29%). The negative likelihood ratio
(NLR) was 0.089 (CI 0.02–0.35), which means that a neg-
ative HCII test for high-risk HPV types is 11 times less
likely in patients with CIN2/3 than in patients without
high grade CIN. This means a negative HPV result by the
HPV DNA HCII test can reduce the probability that a
woman with mild dyskaryosis or borderline smear har-
bours CIN2 or worse from 22.6% to 2.6%.
At a cut-off of 3 RLU performance improved in terms of
specificity, NPV and PPV (see table 2). The negative likeli-
hood ratio (NLR) dropped to 0.072 (CI 0.022–0.24),
which reduces the pre-test probability of 22% for CIN2/3
to 2% post-test probability.
Specificity was higher in women referred for borderline
and in women over 30 years. Sixty-six women in the
cohort were older than 30 years (mean 39y ± 8y). HRHPV
infection was less common in women over 30 years
Table 1: Characteristics of colposcopy population
Histology Referral cytology Age mean ± SD Median of high-risk 
HPV load in liquid 
based cytology (RLU)
Mean high-risk HPV 
load (±SD) in liquid 
based cytology (RLU)
HRHPV DNA > 
1RLU
HRHPV DNA > 
3RLU
64 CIN absent 17 BL 33y ± 11y 1.37 208 ± 509 RLU N = 35 (55%) N = 31 (48%)
47 MD
39 CIN1 5 BL 31y ± 11y 94 446 ± 782 RLU N = 30 (77%) N = 26 (66%)
34 MD
30 CIN2/3 1BL 30y ± 8y 174 568 ± 765 RLU N = 29 (97%) N = 29 (97%)
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Receiver Operator Characteristic curve of high risk HPV HC II for the diagnosis of CIN2/3 in women with minor cytological  abnormalities (red triangles show performance of Pap smears according to KC61 part C, RLU = ratio of relative light units of  specimen to positive controls) Figure 1
Receiver Operator Characteristic curve of high risk HPV HC II for the diagnosis of CIN2/3 in women with minor cytological 
abnormalities (red triangles show performance of Pap smears according to KC61 part C, RLU = ratio of relative light units of 
specimen to positive controls)
Table 2: HRHPV Hybrid Capture II performance for the diagnosis of CIN2/3
referral smear cut off n sensitivity specificity NPV NLR OR
MD & BL 1 RLU 133 97% 37% 97% 0.089 17
MD & BL 3 RLU 133 97% 46% 98% 0.072 26
1xMD 1 RLU 110 97% 36% 97% 0.096 17
1xMD 3 RLU 110 97% 41% 97% 0.083 19
3xBL 1 RLU 23 100% 52% 100% NA NA
3xBL 3 RLU 23 100% 64% 100% NA NA
MD & BL in woman >30y 1 RLU 66 100% 47% 100% NA NA
MD & BL in woman >30y 3 RLU 66 100% 58% 100% NA NA
MD = mild dyskaryosis, BL= borderline, NA = non applicable due to 0 in 2 × 2 table
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(56%) than in younger women (77%). However the dif-
ference was not significant (p > 0.05, Normal test). Specif-
icity reached 58% in women over 30 years.
The expenses for the HRHPV HCII test were weighed
against the savings achieved by less colposcopies. As cost-
ings for colposcopy are defined by the health care resource
group within the NHS, it is possible to calculate the cost
neutral price for one HRHPV HCII test from these savings.
Colposcopy could have been omitted only in 39 to 49 of
133 patients who tested HPV negative for the expense of
133 HPV tests and would miss one CIN2/3 case (see table
3). To be cost neutral the price of the HRHPV HCII test at
a cut-off of 3 RLU must not exceed £34.37 inclusive test
reagents, overheads and staff costs.
If only women over 30 years would be triaged by HRHPV
HCII at a cut-off of 3RLU, the cost neutral price for one
HRHPV HCII test would amount to £41.
Discussion
The present cohort is representative of women referred to
our colposcopy clinic when compared with national audit
figures of the past two years [6,7]. The indication for refer-
ral was in 85% mild dyskaryosis, which reflects the referral
policy after one single mild dyskaryotic Papanicolaou
smear [7]. The CIN2/3 prevalence of 22% was in concord-
ance with 18% in the year 2000 and with 27% in
2001[6,7].
Though the HRHPV viral load rose with increasing grade
of CIN the means did not differ significantly. Natural his-
tory studies showed that the HPV load fluctuates during
the course of infection being low in the beginning and at
the end [8]. To convert the continuous variable into a
HRHPV positive and negative result a ROC plot was con-
structed. The ROC plot suggested an optimal cut-off at
3RLU at which the sensitivity remained high and the spe-
cificity rose to 46%. Two other validation studies of the
HRHPV HCII in women with LSIL also observed that from
1RLU to 2.5RLU the sensitivity remained stable with a
strong increase of specificity in women with LSIL [9,10].
Sensitivity and negative predictive value were very high
with both 97%, and thus a negative HRHPV test can
exclude high grade CIN with a higher frequency than
repeat cytology as shown in a randomised trial [11]. A
quantitative measure to exclude disease is the negative
likelihood ratio (NLR). The NLRs of 0.089 at 1RLU or of
0.074 at 3RLU reduce the pre-test probability of 22% to a
post-test probability of 2%, which means that women
referred for a minor cytological abnormality and a
negative HRHPV HCII test have a chance of 2% to harbour
CIN2/3. If used to triage women with minor cytological
abnormalities for colposcopy, who test HRHPV positive at
a cut off of 3RLU, HRHPV testing would reduce
colposcopy referrals by 36%. This strategy would be cost
neutral in the NHS if the costs for HR HPV testing do not
exceed £34.37 per test.
The specificity of 37% at 1RLU and 46% at 3 RLU resulted
in a poor positive predictive value. The high false positive
rate is due to the high proportion of women who are
infected by HRHPV but will clear the virus and will not
progress to high grade CIN. Low specificity was found in
other studies on women referred to colposcopy for mild
dyskaryosis. Rebello et al. [12] found a specificity of only
39% in mild dyskaryosis but of 76% in borderline refer-
rals. Also Wright et al. [10] could demonstrate at a cut-off
of 1 RLU a specificity of 25% in LSIL referrals in contrast
to 75% in ASCUS. The ALTS trial arm of LSIL was closed
early due to the high HPV positive rate of the HRHPV
HCII test [13]. CIN is more prevalent in women with mild
dyskaryosis than with ASCUS or borderline changes.
Table 3: Cost comparison of different management strategies and cut offs
Colposcopy in all 
women with minor 
cytol. disorders 
without HPV testing
Colposcopy only in 
HPV positive (≥1RLU) 
women with minor 
cytol. disorders
Colposcopy only in 
HPV positive (≥3RLU) 
women with minor 
cytol. disorders
Colposcopy in women 
over 30 y with minor 
cytol. disorders 
without HPV testing
Colposcopy only in 
HPV positive (≥3RLU) 
women over 30 y with 
minor cytol. disorders
No. of colposcopies 133 94 84 66 37
No. of HPV tests 0 133 133 0 66
Costs of colposcopies £12407 £8768 £7835 £6156 £3451
Savings by omitting 
colposcopies in 
women who test 
HRHPV negative
0 £3639 £4572 0 £2705
Cost neutral price for 
1 HRHPV HCII test 
(savings/No. of HPV 
tests)
£27.35 £34.37 £41
No of CIN2 or worse 
detected
30 29 29 16 16BMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/23
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To reduce the false positive rate HRHPV testing could be
confined to women with borderline changes, which are
more frequently due to reactive changes than to CIN. The
specificity rose to 63% in this subgroup. This trend is con-
sistent with results of other evaluation studies in women
with ASCUS in which the specificity figures ranged
between 64–75% [14,15]. However, as borderline
changes are only less than 20% for gynaecological referral
in our setting, this strategy will not serve the majority of
women referred to the colposcopy clinic at WMUH.
Previous studies could show that the performance of
HRHPV testing for the diagnosis of CIN2/3 is better in
women over 30 years, because women at this age should
have cleared primary infection and if still HRHPV positive
may be at risk of persistent infection with progression.
Fifty percent of women referred to colposcopy were over
30 years old with a mean age of 39 years. At a cut-off of 3
RLU specificity reached 58% and thus 44% of women
over 30 years who tested HPV negative could have been
excluded from colposcopy. This is in concordance with
Cuzick's [9] previous large UK evaluation studies in
women over 35 years (mean age = 46 years).
Conclusion
The diagnostic value of the HRHPV HCII is based on a
negative result predicting absence of CIN2/3 with an
excellent negative predictive value of 97%, which reduces
the probability of CIN2/3 from 22% to 2% in women
with minor cytological disorders. As the majority of
HRHPV infected women will clear the virus, the HRHPV
HCII test is not specific for progression of infection to
high grade CIN in women with minor cytological abnor-
malities. However persistence of HRHPV infection after
the age of thirty years has a moderate positive predictive
value and could reduce gynaecological referrals in this
subgroup by 44% on the basis of a negative HRHPV test
result. In future susceptibility to cervical cancer such as
HLA type or cellular progression markers may be more
specific and predictive for progression to high grade CIN
than HRHPV testing in women with minor cytological
disorders.
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